Golden, Colorado—November 21, 2017 Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma, announced the filing of a USPTO patent application regarding a novel stem cell line and its application to treatment of a variety of conditions including skeletal muscular, neurological, immune system dysfunction and other diseases or injuries as well.  The new stem cell line is derived from adult stem cells that are naturally present in the body in bone marrow, teeth, cord blood, fat and other tissues as well.  Several clinical trials have been conducted by others using similar stem cells and early results indicate safety and efficacy.  Our new stem cells are also being used in clinical trials as well and the initial results support further continuation of these trials.

Vitro Biopharma scientists have also developed proprietary methods to differentiate these adult stem cells into other cells with clinical promise including neural stem cells (NSCs) for use in treatment of various neurological conditions.  Recent clinical trials support safety and efficacy of targeted administration of NSCs in the treatment of stroke.  We have also developed proprietary methods to differentiate our patent-pending stem cell line into kidney and cardiac cells with potential therapeutic applications in the treatment of kidney and heart disease respectively.

Dr. Jim Musick, Ph.D., President and CEO of Vitro Biopharma said, “We are pleased with the new addition to our expanding intellectual property portfolio that now includes processes for stem cell transplant, activation and biomarker tracking.  This allows us to follow an adult stem cell transplant with further therapy to activate or differentiate the implanted stem cells to enhance and maximize the therapeutic benefit of a stem cell transplant.  Biomarker profiling of the stem cells enables quantitation of stem cell status and measurement of therapeutic effects.  Our initial phase I study of autism provided preliminary evidence of safety and efficacy of our stem cell activation protocol.  While these studies are also being expanded, there is further clinical evidence also suggesting that stem cell transplants may be effective in treating ASD.  Our platform of stem cell transplants, together with post-transplant activation/differentiation and advanced molecular diagnostics offers numerous unique advantages to optimize stem cell therapies of autism and other diseases as well.”

John Evans, Vitro Biopharma’s CFO said, “This represents our continued  progress forward in turning our Research and Development into viable stem cell treatment products to contribute to Vitro’s growth going forward”


About Vitro Biopharma

Vitro Biopharma’s ( mission is “Harnessing the Power of Cells™” for the advancement of regenerative medicine to its full potential. Vitro Biopharma operates within a modern, GMP-compliant biotechnology manufacturing and R&D facility in Golden, Colorado.  Vitro Biopharma manufactures and sells “Tools for Stem Cell and Drug Development™”, including human mesenchymal stem cells and derivatives, the MSC-Gro™ Brand of optimized media for MSC self-renewal and lineage-specific differentiation.  Our cell lines also include cancer-associated fibroblasts (CAFs) derived from lung, colorectal, ovarian, uterine, breast, melanoma and pancreatic tumors.   In addition, we provide MSC-derived progenitor cells, including neural stem cells (NSCs), nephron progenitor cells (NPCs) as well as a growing line of terminally differentiated cells: cholinergic and dopaminergic neurons, osteoblasts, chondrocytes, cardiomyocytes, and renal tubular epithelial cells.  An application of these terminally differentiated cells is cell-based assays for drug discovery and pre-clinical toxicology of drugs, drug candidates and drug combinations that may produce toxic effects on cardiac, neural or renal cells, either directly or through metabolites derived from the interaction of drugs with specific cells such as liver cells.  Vitro Biopharma also developed its Clinical Grade MSC-Gro™ Media for expansion of stem cells prior to transplantation for clinical studies of osteoarthritis treatment and products for use in studies of stem cell activation therapy for ASD & autoimmunity.

Vitro Biopharma received the Frost and Sullivan Technology Innovation Leadership Award for the industry sector: Stem Cell Tools and Technology in North America, 2014.

Mission Statement: “As a leader in stem cell technology we manufacture and distribute multiple stem cell therapies for the treatment of degenerative diseases.”


Forward-Looking Statements

Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company’s auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements”.  Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures.  Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission.  Most of these factors are outside the control of the Company.  Investors are cautioned not to put undue reliance on forward-looking statements.  Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.



Dr. James Musick

Chief Executive Officer

Vitro Biopharma

(303) 999-2130 Ext. 3


Source: Vitro Diagnostics, Inc.